Sysmex to Participate in the Global Health Innovative Technology Fund
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) provides notice of its decision to participate in the Global Health Innovative Technology Fund (GHIT Fund).
Rapid globalization in recent years has led to an increase in diseases crossing national borders, which has become a global problem. As part of the international community's initiatives in this regard, one of the United Nation's Millennium Development Goals is to halt the spread of HIV/AIDS, malaria and other diseases.
Sysmex is working on development of testing technologies targeting malaria, dengue fever, HIV and other diseases, as well as developing products to contribute to the diagnosis of infectious diseases in emerging markets and developing countries.
Sysmex has decided to participate in the GHIT Fund, which states its vision as "one in which the crushing burden of infectious disease no longer prevents billions of people in the developing world from seeking the level of prosperity and longevity now common in the industrialized world."
The GHIT Fund is the first Japanese public-private partnership, with members including representatives from the Japanese government, the United Nations Development Programme (UNDP), the pharmaceutical industry, and the Bill & Melinda Gates Foundation. By promoting collaboration among Japanese and overseas research institutions and providing grant funding, the GHIT Fund encourages drug discovery and the development of diagnostic reagents.
Sysmex has agreed to participate in the fund; assisting in the application of Japanese technological innovation to healthcare in developing countries. Sysmex participates as the only diagnostic reagents company in the fund. The Company will contribute to the GHIT Fund by providing donations and participating as a product development partner for a three-year period from 2015. Sysmex is sure that the participation in the GHIT Fund leads to searching the possibility to utilize our diagnostic reagents technologies for infectious diseases and thus will contribute to global healthcare standardization and quality improvements.
Sysmex continues providing trust and confidence to customers of the world, including developing countries, by contributing to standardization and improved quality of healthcare.
About the GHIT Fund
The Global Health Innovative Technology Fund (GHIT Fund) is an international non-profit organization that promotes Japanese drug discovery and development with the aim of controlling infectious diseases that are particularly widespread in developing countries, including AIDS, tuberculosis, malaria and neglected tropical diseases (NTDs). See https://www.ghitfund.org/en for more details on the GHIT Fund.